// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Audit of Duration of Corticosteroid Treatment in Acute Exacerbations of COPD

Suman Paul - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Predictors of pleurodesis success

Rachel Mercer - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis

Taha Lodhi - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Electronic monitoring devices: the saviour of poor control in asthma?

Ireti Adejumo - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Home monitoring of respiratory rate from pulse oximetry in children with cystic fibrosis

David Wertheim - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

N/A

Influence of gender on lung function in prematurely born young people

Christopher Harris - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

No single system of Pulmonary Rehabilitation delivers for all Patients with COPD ?

Michael Apps - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Effects of intravenous iron on hypoxic pulmonary vasoconstriction and maximal exercise capacity during sustained (8 h) hypoxia in healthy volunteers.

Nick Talbot - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Iron sucrose

COPD exacerbations in the phase 3 revefenacin clinical trial program

James F. Donohue - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Revefenacin

Indoor airborne microbiota composition associated with asthma and atopy in rural children

Alejandro Dorado Garcia - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Asthma

N/A

Asthma control is associated with smoking status: Findings from WATCH

Yvette Thirlwall - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Depression

N/A

Sedentary behaviour is associated with worse cardiometabolic profiles in COPD patients, irrespective of moderate intensity physical activity

Daniel R. Burrage - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Assessment of ventilatory mechanics in respiratory muscle weakness using structured light plethysmography

James Stockley - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Smoking and severe persistent asthma

Paraskevi Katsaounou - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Depression

N/A

Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection.

Alexander Mathioudakis - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Suppressor of cytokine signalling 1 (SOCS1) and asthma exacerbations

Kate Strong - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST

Ian Douglas Pavord - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Dupilumab

Sarcoidosis treatment and outcomes: what is most important to patients?

Jeanette Boyd - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sarcoidosis

N/A

Small airway fibroblasts from COPD patients are senescent and pro-fibrotic

Catherine Wrench - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The role of ASC signalling in preterm infants at risk of chronic lung disease of prematurity

David Gallacher - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved